A

transatlantic initiative devoted to underwriting new antibiotics and other treatments to tackle drug-resistant infections in developing countries received a big boost Tuesday when the Bill and Melinda Gates Foundation and the U.K. government agreed to fund the effort.

The CARB-X project, which was created two years ago and later secured $455 million in funding from the U.S. government and a public-private partnership in the U.K., is now slated to receive an additional $52 million that will also be invested in getting new treatments into humans in clinical trials.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy